Kornimate/medical-research-clean huggingface dataset:
extracranial carotid & intracranial arterial stenosis in ischemic stroke

Conditions: Ischemic Stroke; Carotid Stenosis

Summary: the aim of the work is to; elucidate how the presence of carotid stenosis influence the pattern of stroke and also how it interact with other risk factors for stroke. also identify predictors of intracranial stenosis and outcome in patients with carotid stenosis with or without intracranial stenosis.

patients: ischemic stroke patients admitted to neurology department in mansoura university hospital (muh) will be studied the patients will be grouped as follow: 1. patients with significant carotid stenosis without intracranial stenosis. 2. patients with carotid and intracranial stenosis. 3. patients with lone intracranial stenosis. 4. patients with no significant carotid or intracranial stenosis. methods: studied patients will undergo the following: * clinical assessment with nih scale with is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit, modified rankin scale, arabic version of montereal coginitive assessment and arabic version of beck's depression inventory at presentation and after 6 months. * carotid duplex+/- mra neck and brain mra+/-ct angio on carotid and brain (at 0day) and 6m after. * mri brain with diffusion to detect asymptomatic stroke at 0 day and 6 months later. * dsa (digital subtraction angiography) in some cases to confirm diagnosis. * laboratory investigations: complete blood count, liver function and renal function tests, random blood sugar, lipid profile. all patients will be treated with acetyle-salicylic acid(150/day) +/-clopidogrel (75mg /day) +/- statins, plus modification of risk factors.

Eligibility criteria:
inclusion criteria: * carotid tia (transient ischemic attack) it should, however, be focal and usually motor-sensory to implicate the carotid artery system or ischemic stroke involving carotid territory. * asymptomatic patients with carotid stenosis or anterior circulation stenosis discovered accidentally during investigations for further risk factors. exclusion criteria: * major functional impairment (modified rankin scale \>/= 3) * significant cognitive impairment. * contraindication to acetylsalicylic or dual antiplatelet. * renal dysfunction precluding safe contrast medium administration. * pregnancy or refusal. * intracranial aneurysm or avm. * intra cerebral hemorrhage or hemorrhagic infarction.

Keywords: ischemic stroke carotid stenosis
gynecological sentinel lymph nodes ceus

Conditions: Cervical Carcinoma; Malignant Female Reproductive System Neoplasm; Vaginal Carcinoma; Vulvar Carcinoma

Summary: this clinical trial compares the use of ultrasound for the detection of sentinel lymph nodes (slns) to the standard of care (which varies depending on cancer treatment). the ultrasound contrast agent is called sonazoid and it consists of tiny gas-filled bubbles about the side of red blood cells. diagnostic procedures, such as ultrasound with sonazoid, may help identify more slns than standard of care in patients with cervical, vaginal, or vulvar cancer.

primary objectives: i. to determine the concordance between lymphosonography and the standard of care in the identification sentinel lymph nodes (slns) in patients with cervical, vaginal or vulvar cancer. ii. to determine if lymphosonography can identify more slns with metastatic deposits in patients with cervical, vaginal or vulvar cancer when compared to the standard of care. outline: patients receive perflubutane microbubble (sonazoid) injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment. after completion of study intervention, patients are followed up for 30 days.

Eligibility criteria:
inclusion criteria: * be female * be diagnosed with cervical, vaginal or vulvar cancer * be at least 18 years of age * if of child-bearing potential, must have a negative pregnancy test * be able to comply with study procedures * have read and signed the institutional review board (irb)-approved informed consent form for participating in the study exclusion criteria: * females who are pregnant or nursing * patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours afterwards * patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. for example: * patients on life support or in a critical care unit * patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia * patients with recent cerebral hemorrhage * patients who have undergone surgery within 24 hours prior to the study sonographic examination * patients with congenital heart defects * patient with a known allergy to sonazoid (including an anaphylactic allergy to eggs or egg products)
the effect of head and shoulder positioning on the cross-sectional area of the subclavian vein in obese adults

Conditions: Normal Volunteers

Summary: in the present study, the cross-sectional area of subclavian vein, and the depth of the scv from the skin are assessed in different head positions (neutral, rotation to ipsilateral or contralateral sides) and different shoulder positions (neutral or lowered) in spontaneous breathing obese adults.


Eligibility criteria:
inclusion criteria: * healthy obese adults (bmi ≥ 30) exclusion criteria: * medication affecting vascular elasticity history of central venous catheterization or clavicle fracture history of lung surgery, operation of chest cage
pancreatic duodenal homeobox factor-1 (pdx-1) and neurogenin-3 (ngn-3) in gestational diabetes

Conditions: Gestational Diabetes

Summary: introduction: depletion of the ability of the cells ß to secrete the amount of insulin required by pregnancy, increasing the risk of develop gestational diabetes mellitus (gdm). the aim was to contrast the messenger rna (mrna) expression of the pancreatic duodenal homeobox factor-1 (pdx-1) and neurogenin-3 (ngn-3) in peripheral blood of pregnant women with gdm versus women with normal pregnancies. material and methods: this was a prospective, clinical and cross-sectional study, conforming two groups of pregnant women: a) patients with a healthy gestation and b) patients with gdm. besides anthropometry and routine laboratorial test, real-time polymerase chain reaction (real-time pcr), was used to quantify the expression of pdx-1 and ngn-3.

pregnant women attended in the maternal-fetal medicine service of the "mónica pretelini sáenz" maternal-perinatal hospital, were invited to participate. those with autoimmune diseases, heart disease, nephropathy, liver disease or any other chronic condition were excluded and those with incomplete clinical files were discarded from the final analysis. two groups were integrated: a) patients with a healthy gestation and b) patients with gdm. from all patients the next information was captured in an excell sheet: weight, height, body mass index, blood pressure, albumin, creatinine, electrolytes, glucose, total cholesterol, triglycerides, transaminases and relative expression of pdx-1 and ngn-3.

Eligibility criteria:
inclusion criteria: * pregnant women older than 18 years old. exclusion criteria: * those with autoimmune diseases, heart disease, nephropathy, liver disease or any other chronic condition.

Keywords: pdx-1 ngn-3 glucose
systematized quality exercise alternatives for stress incontinence

Conditions: Stress Urinary Incontinence; Pelvic Floor; Weak; Incontinence, Urinary; Quality of Life

Summary: this randomized controlled study evaluates the effect of home biofeedback compared to pelvic floor physical therapy for the treatment of stress urinary incontinence. half of the participants will use a home biofeedback device for 3 months and the other half will attend pelvic floor physical therapy appointments for 3 months.

biofeedback has been shown to be highly effective the treatment of stress urinary incontinence when used in conjunction with pelvic floor physical therapy under the instruction of a healthcare provider. home biofeedback has not been well studied, even though several fda cleared devices are on the market and available for patients to purchase. it is unclear if the biofeedback improves women's urinary incontinence, or if the increased contact with a healthcare provider causes the improvement. using a home biofeedback device, a woman places the device in her vagina and contracts the muscles of her pelvic floor to improve the strength, which can improve or cure incontinence when performed over time. typically it takes 3 months for benefit to be seen.

Eligibility criteria:
inclusion criteria: * female subjects \>18 years of age * sui or mixed ui with stress predominant symptoms and more bother by the sui * english speaking/reading * own a smartphone that can support phone application and bluetooth for the biofeedback device * willing to come for 4 pfpt visits over 3 months if randomized exclusion criteria: * prior anti-incontinence surgery * had prior pelvic floor physical therapy for sui * prolapse of any compartment noted below the hymen * inability to speak/understand english * pregnant * decline or unable to return for frequent pt visits during study period * unable to be contacted for follow up by telephone * neurologic disorders known to cause neurogenic bladder
encapsulated acellular system from mesenchymal stem cells for dental pulp regeneration

Conditions: Periapical Periodontitis

Summary: to evaluate the security and efficacy in the administration of encapsulated acellular system derived from mesenchymal stem cells as a novel regenerative endodontic procedure which to promote the pulpar regenration.


Eligibility criteria:
inclusion criteria: * systemically healthy patients (asa i). * patient presenting with a maxillary or mandibular incisor/canine and mandibular premolar with mature apex, pulpal necrosis, and apical radiographic evidence of apical periodontitis (pai ≥2 and cbctpai ≥1). * patient presents with a tooth that does not respond to electrical and thermal pulp testing. * patients with restorable teeth (considering the definition of class a or b, according to samet and jotkowitz classification) without the need for a single fine prosthesis (crown) or major restoration. exclusion criteria: * patients not available for the follow-up period (27 weeks). * patients who will undergo orthodontic treatment in the next six months. * patients with reports of allergies to any material or medication used in the study. * pregnant patients. * heavy smokers (more than 10 cigarettes per day). * patients with a history of systemic diseases that impair immune function, such as diabetes mellitus, immunodeficiency, leukemia, addison's and cushing's disease. * patients who have used immunosuppressive drugs or chemotherapy, 3 months before the study. or that they will be irradiated or undergo chemotherapy. * patients who have endodontically treated teeth. * patients who have teeth with signs of severe root resorption. * patients who have teeth with mobility class iii or dens invaginatus. * patients who have teeth with a history of avulsion-type dentoalveolar trauma. * patients who have teeth with clinical and/or radiographic evidence of root fracture. * patients who have teeth that cannot be completely isolated with rubber dam. * patients who have teeth with more than one root or root canal.

Keywords: mesenchymal stem cells regenerative procedures dental pulp pulp regeneration allogenic acellular system
efficacy and safety assessment of t4030 eye drops versus ganfort® ud in ocular hypertensive or glaucomatous patients.

Conditions: Ocular Hypertension Glaucoma

Summary: to demonstrate the non-inferiority of t4030 unpreserved eye drops compared to ganfort® ud in terms of efficacy.

efficacy parameters iop assessment in each eye

Eligibility criteria:
inclusion criteria: * informed consent signed and dated\* * patient aged ≥18 years old * both eyes with a central corneal thickness assessment ≥500 µm and ≤600 μm a * both eyes with diagnosed ocular hypertension or open angle glaucoma exclusion criteria: * history of narrow angle and/or angle closure glaucoma * advanced stage of glaucoma
phase ii study of high-dose cyclophosphamide in patients with severe autoimmune hematologic disease

Conditions: Anemia, Hemolytic, Autoimmune; Felty Syndrome; Purpura, Thrombocytopenic; Autoimmune Diseases

Summary: objectives: i. determine the response rate and 1-year event-free survival in patients with severe autoimmune hematologic disease treated with high-dose cyclophosphamide.

protocol outline: patients receive high-dose cyclophosphamide iv on days 1-4 and filgrastim (g-csf) starting on day 10 and continuing until blood counts recover. patients are followed at 1, 3, 6, and 12 months and then annually thereafter.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * diagnosis of severe autoimmune hematologic disease autoimmune hemolytic anemia or immune thrombocytopenia * failure of at least 2 standard treatment approaches (e.g., prednisone therapy, splenectomy, intravenous immunoglobulin, or other immunosuppressants) * inability to taper prednisone dose to less than 10 mg/day or autoimmune neutropenia including the following: felty's syndrome or disorders of large granular lymphocytes with recurrent infections or absolute neutrophil count less than 200/mm3 --prior/concurrent therapy-- * see disease characteristics --patient characteristics-- * age: not specified * performance status: not specified * hematopoietic: see disease characteristics * hepatic: not specified * renal: creatinine no greater than 2.5 mg/dl * cardiovascular: ejection fraction at least 40% * pulmonary: fvc, fev1, or dlco at least 50% predicted other: * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * not preterminal or moribund

Keywords: felty syndrome autoimmune hemolytic anemia autoimmune neutropenia hematologic disorders immune thrombocytopenic purpura rare disease
indirect resin composite inlays cemented with a self-adhesive, self-etch or a conventional resin cement

Conditions: Dental Leakage

Summary: the present study was designed to provide further evidence in this particular research prospective, and this study hence aimed to clinically evaluate the 5-years adhesion durability of indirect resin composite inlays luted with three different resin cement strategies in mod class ii restorations. the formulated null hypothesis was that there is no significant difference in the clinical performances of the three different resin cement strategies for luting indirect resin composite inlays in mod class ii restorations for 5-years. the research question was as follows: do self-adhesive resin cements in class ii restorations present better clinical performances than conventional etch-and-rinse and self-etch resin cements according to the usphs criteria?

objective: to clinically evaluate the 5 years adhesion durability of indirect resin composite inlays luted with three different resin cement strategies in mod class ii restorations. materials and methods: a randomized clinical trial was conducted following the protocol, 40 patients with three large cavities for each one that indicated for indirect mod class ii restorations were enrolled in the current study. then, 120 indirect resin composite inlay restorations (sr nexco) were placed and luted with three different resin cement strategies; an etch-and-rinse (variolink n), self-etch (panavia f2.0) and self-adhesive (relyx unicem). each resin cement was used for luting 20 inlay restorations. a single operator placed all restorations according to the manufacturer's instructions. immediatelly after placement, the restorations were finished and polished. clinical evaluation was performed at baseline and at 1, 3 and 5 years intervals after placement by two independent examiners using modified usphs criteria. the changes in the usphs parameters during the 5 years period were analyzed with fredman test. the baseline scores were compared with those at the recall visits using wilcoxon signed rank test, where the level of significance was set at p˂0.05.

Eligibility criteria:
inclusion criteria: * patients with primary caries involving occlusal surface only with icdas 2 and 3. * patients with cavities no more than one-third of the intercuspal distance. * patients must have a good oral hygiene. * patients with tooth gives positive response to testing with an electric pulp tester. * patients with normal and full occlusion. * patients with opposing teeth should be natural with no restorations. exclusion criteria: * high caries risk patients with extremely poor oral hygiene. * patients involved in orthodontic treatment or periodontal surgery. * patients with periodontally involved teeth (chronic periodontitis). * patients with abutments should be excluded. * patients with heavy bruxism habits and clenching.

Keywords: resin composite randomized clinical trial operative dentistry
ultrasound guided transversus abdominis plane block in pediatric surgery

Conditions: Postoperative Pain

Summary: the primary objective of this study is to assess differences in postoperative pain experienced by pediatric patients having transversus abdominis plane block block with bupivacaine (0.125% and 0.25%) compared with control group will receive conventional iv analgesia after laparoscopic surgery.

a prospective randomized controlled double blind study using a computer generated randomization will be conducted in assiut university hospitals and carried on 60 pediatric patients undergoing laparoscopic surgery under general anesthesia. after induction of general anesthesia and endotracheal intubation, patients in group b and group c will be placed in the supine position and transversus abdominis plane block will be performed under ultrasound guidance. after skin preparation, the linear ultrasound probe connected to a portable ultrasound unit will be placed in the axial plane across the mid-axillary line midway between the costal margin and the highest point of iliac crest. needle attached to a syringe filled with the local anesthetic solution will be inserted until it reaches the plane between the internal oblique and transversus abdominis muscles. after careful aspiration to exclude vascular puncture, injection of bupivacaine will be performed leading to separation between the internal oblique and the transversus abdominis muscles which will appear as a hypoechoic space on ultrasound. this procedure will be repeated on the opposite side . laparoscopic procedure will be started 20 minutes after completion of bilateral transversus abdominis plane block and 0.01 mg/kg iv atropine will be given before pneumoperitonem. intra abdominal pressure will be maintained at 10-12 mmhg. the use of opioids during the procedure will based on the cardiovascular response to stimulation; a heart rate increase of 20% from baseline will be interpreted as insufficient analgesia and will be treated with fentanyl in doses of 1mcg / kg.

Eligibility criteria:
inclusion criteria: * asa i-ii physical status patients. * genders eligible for study :male. * all children scheduled for laparoscopic surgery between the ages of 1and 5 years. * duration of laparoscopic procedure not exceeding 90 minutes. * written informed consent from parent of guardian . exclusion criteria: * sensitivities to local anesthetics. * significant renal, liver, or cardiac disease. * surgery requiring an open procedure

Keywords: tap block pediatric laparoscopic postoperative pain
effect of dexmedetomidine on emergence agitation in children with or without tube insertion under general anesthesia

Conditions: Myringotomy

Summary: the investigators are inviting your child to participate in this research study because your child is having myringotomy (putting a tiny incision in the eardrum with or without tube insertion) under general anesthesia. the purpose of this study is to determine whether a single injection of dexmedetomidine (study medication) decreases the frequency of awaking from anesthesia frightened or agitated in children having myringotomy surgery as compared to those children who receive placebo (sterile saltwater).

emergence agitation (ea) is common in children, especially in the preschool age group who undergo general anesthesia. it has been described as a mental disturbance during the recovery from general anesthesia and can consist of hallucinations, delusions and confusion in the child. to the parent or caregivers this may be seen as moaning, restlessness, involuntary physical activity \& thrashing about in bed. emergence agitation (ea) can result in the child losing their intravenous therapy (iv) access \& bodily injury. some agitated children may retain vivid memories about their negative experience waking up from anesthesia. this can result in seeing new behaviors by the child such as anxiety, nighttime crying and temper tantrums. dexmedetomidine given as an injection into the muscle of children is considered investigational, which means it hasn't been approved by the u.s. fda for treatment of this problem in children. immediately following surgery measurements of eye contact, purposeful actions, aware of surroundings, restless and crying are observed and recorded using the pediatric anesthesia emergence delirium (paed) scale in pacu. follow-up is made approximately 3 days after surgery by phone call or/and email with parent(s) to see if child has experienced any of the following: sleep disturbances, anxiety, eating disturbances, postoperative muscle pain or swelling at the injection site.

Eligibility criteria:
inclusion criteria: * asa i or ii (american society of anesthesiology classification asa i means patients without systemic disease, asa ii means patients with one controlled systemic medical disease eg: diabetes, hypertension.) * between the ages of 1 and 10 years * undergoing bmt under general anesthesia. exclusion criteria: * asa iii or higher (patients with 2 or more medical systemic disease that is not under control, eg: uncontrolled diabetes) * congenital diseases * coagulation disorders * known allergic reaction to dexmedetomidine * serious preexisting impairment of respiratory, cardiovascular, hepatic, renal, neurological or endocrine functions * severe upper airway infection * predicted difficult airway * preexisting psychiatric disorders

Keywords: dexmedetomidine emergence agitation myringotomy children general anesthesia